THE US FDA has granted
accelerated approval for Keytruda
(pembrolizumab) to treat patients
with advanced non-small cell
lung cancer whose disease has
progressed after other treatments,
and with tumours that express a
protein called PD-L1.
Keytruda has been approved for
use with a companion diagnostic,
the PD-L1 IHC 22C3 pharmDx test,
the first test designed to detect
PD-L1 expression in non-small cell
lung tumours.The above article was sent to subscribers in Pharmacy Daily's issue from 06 Oct 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Oct 15
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.